TGFB1 and renal fibrosis: A variety of drugs that directly target renal fibrosis have been tested in clinical trials, such as fresolimumab (a human monoclonal antibody anti-TGF-β) and STX100 (a humanized anti-α5β6 integrin antibody) [10,11], but none of these drugs can be used in the clinic yet due to safety and efficacy concerns.